Biosig Technologies Inc

BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioSig Technologies Inc said that its PURE EP System has exceeded its procedural target of 1,500 patient cases in 2021. As of October 21, 2021, the PURE EP System had been used in over 1,560 patient cases by 71 physicians, up from 1,000 cases in June 2021, when the procedural guidance was raised amid increased technology usage in elective procedures.

BioSig Technologies says its PURE EP System has exceeded its procedural target of 1,500 patient cases in 2021

The Company reports increased adoption and commercial activity of its signal processing technology for arrhythmia care The Company reports increased adoption and commercial activity of its signal processing technology for arrhythmia care

BioSig Increases Case Volume Estimates

BioSig Technologies, Inc . (NASDAQ: BSGM) announced that an article titled "Evaluation of a Novel Cardiac Signal Processing System for Electrophysiology Procedures: The PURE EP 2.0 Study" has been published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access as of September 23, 2021, via the Wiley Online Library.

Clinical Data Published in the Journal of Cardiovascular Electrophysiology Could Be Important for This Stock

BioSig Technologies, Inc. has said its flagship  PURE EP System technology will be featured in a live patient case streamed during the 16th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy (VT 2021), held virtually on October 15-16, 2021.

BioSig Technologies says its flagship technology to be featured in a live patient case streamed during the 16th Annual International Symposium on Ventricular Arrhythmia

Company's signal processing technology for arrhythmia care to be featured during the event co-hosted by the University of Pennsylvania and The Mount Sinai Hospital Company's signal processing technology for arrhythmia care to be featured during the event co-hosted by the University of Pennsylvania and The Mount Sinai Hospital

BioSig's PURE EP System to be Featured in a Live Patient Case During Annual International Symposium on Ventricular Arrhythmias

Plexus

Photo by Anna Shvets from Pexels With the recent successes of its PURE EP™ system underway, BioSig Technologies Inc. (NASDAQ: BSGM) has effectively gone global.

BioSig Inks Manufacturing Deal with Plexus Corp

BioSig Technologies Inc. has announced that clinical data acquired by its PURE EP System has been published in the Journal of Cardiovascular Electrophysiology.

BioSig says clinical data acquired by its PURE EP System published in Journal of Cardiovascular Electrophysiology

The PURE EP™ System is validated in multi-center study as superior to conventional sources of intracardiac signals The PURE EP™ System is validated in multi-center study as superior to conventional sources of intracardiac signals

Clinical Data Acquired by the PURE EP™ System Published in the Journal of Cardiac Electrophysiology

BioSig Technologies Inc. said it has entered into a manufacturing and professional services agreement with Plexus Corp.

BioSig Technologies selects Wisconsin-based Plexus Corp. as its manufacturing partner

Global leader in complex product design, supply chain, manufacturing, and aftermarket services to support the Company's growth Global leader in complex product design, supply chain, manufacturing, and aftermarket services to support the Company's growth

BioSig Selects Plexus Corp. as its Manufacturing Partner

Image by PublicDomainPictures from Pixabay  An estimated 33.5 million individuals worldwide and nearly 2.7 million people in the U.S. live with an often silent, untreated medical issue.

BioSig's PURE EP Aims to Address Unmet Needs of Afib Patients

BioSig Technologies Inc, which is commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has announced the appointment of Dr James Barry as an independent board director. The company said Dr Barry has more than 30 years of experience in the medical device industry as an executive and corporate board director.

BioSig Technologies appoints medical-device industry executive James Barry as independent board director

James J. Barry, Ph.D. will join as an Independent Director as Company expands clinical footprint with its signal processing technology for arrhythmia care James J. Barry, Ph.D. will join as an Independent Director as Company expands clinical footprint with its signal processing technology for arrhythmia care

BioSig Technologies, Inc. Appoints Medical Device Industry Leader to its Board of Directors

Increasing its ever-growing presence in the cardiac electrophysiology space, BioSig Technologies (NASDAQ: BSGM) will be installing one of its new PURE EP systems in St. Elizabeth's Medical Center in Boston for evaluation. Physiological pacing procedures are meant to mimic the heart's normal contraction to have markedly improved clinical and hemodynamic benefits.

BioSig Expands in Electrophysiology with St. Elizabeth's Medical Center Evaluation

BioSig Technologies Inc said it would install a PURE EP System for evaluation at St. Elizabeth's Medical Center in Boston.  The company said it initiated the new evaluation program under the leadership of Dr.

BioSig to install PURE EP System for evaluation at St. Elizabeth's Medical Center in Boston

BioSig Technologies, Inc. said it has been invited to participate in The Mark E.

BioSig Technologies says to participate in The Mark E. Josephson Twenty-Eight Annual State-of-the-Art Arrhythmia Symposium

Physician-only event, organized by the University of Pennsylvania, is a tribute to the pioneer of cardiac electrophysiology Physician-only event, organized by the University of Pennsylvania, is a tribute to the pioneer of cardiac electrophysiology

BioSig Confirmed as a Participant of The Mark E. Josephson Twenty-Eight Annual State-of-the-Art Arrhythmia Virtual Symposium

A physician user from a leading medical center of excellence will present the technology and discuss recent clinical data A physician user from a leading medical center of excellence will present the technology and discuss recent clinical data

BioSig's Signal Processing System for Arrhythmia Care To Be Featured At The Kansas City Heart Rhythm Symposium

Confirmed speakers include the largest technology users from Mayo Clinic, Texas Cardiac Arrhythmia Institute, and University of Pennsylvania Confirmed speakers include the largest technology users from Mayo Clinic, Texas Cardiac Arrhythmia Institute, and University of Pennsylvania

BioSig To Host Presentations from Physician Users of its Signal Processing System for Arrhythmia Care during the annual Heart Rhythm 2021 convention

BioSig Technologies Inc (NASDAQ:BSGM) has announced the signing of a new agreement for the clinical evaluation of the company's PURE EP technology for arrhythmia care at Medical City North Hills in North Richland Hills, Texas. As part of the evaluation agreement, Medical City North Hills clinical representatives will provide on-site training and assist with data collection and interpretation and workflow customization for every physician and all electrophysiology lab staff members to ensure optimal user experience.

BioSig Technologies expands Texas clinical footprint for its PURE EP technology for arrhythmia care

Texas installation builds as company adds team members to support installations around major metropolitan areas Texas installation builds as company adds team members to support installations around major metropolitan areas

BioSig Latest Installation Broadens Clinical Footprint for its Signal Processing Technology for Electrophysiology

Westport, CT, July 12, 2021 (GLOBE NEWSWIRE) -- ﻿BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a call to discuss the recent conclusions of its PURE EP(tm) 2.0 study, which enrolled 51 patients at Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, TX, Mayo Clinic Florida Campus in Jacksonville, FL and Massachusetts General Hospital in Boston, MA.

BioSig to Host Conference Call to Unblind Clinical Data Collected with its Signal Processing Technology for Arrhythmia Care

BioSig Technologies Inc (NASDAQ:BSGM) announced that it has installed its PURE EP ECG signal processing platform system at New York-Presbyterian/Weill Cornell Medical Center in New York. Weill Cornell Medical Center, which began conducting patient cases with the PURE EP System in June 2021, offers one of the most extensive electrophysiology programs in the country, the company said.

BioSig installs PURE EP system at New York hospital as part of northeast commercial launch

The Company installs its novel medical technology platform for arrhythmia care in a leading Center of Excellence The Company installs its novel medical technology platform for arrhythmia care in a leading Center of Excellence

BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology

According to a recently filed 8-k, BioSig Technologies, Inc. (NASDAQ: BSGM) received a new purchase order from the Mayo Foundation for medical education and research. The institution commenced the evaluation of the PURE EP™ System in April 2021.

News for Biosig Technologies Inc Stock (BSGM)